Topic: gpcr targets

Antiverse Secures $9.3M to Scale AI-Powered Antibody Discovery

Antiverse, a Cardiff-based biotech firm, has secured a $9.3 million Series A investment to scale its AI-driven drug discovery platform and advance internal therapeutic programs. The company specializes in using machine learning to design therapeutic antibodies for challenging protein targets, suc...